Evidence map›Paper›PMID 39766093›Full record

ArticleCancers2024

Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis.

Rusia Lee, Viola Ellison, Dominique Forbes, Chong Gao, Diana Katanov, Alexandra Kern, Fayola Levine, Pam Leybengrub, Olorunseun Ogunwobi, Gu Xiao and 2 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rusia LeeDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.ORCID 0000-0002-5376-1888
Viola EllisonDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.ORCID 0000-0002-4275-5570
Dominique ForbesDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Chong GaoDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Diana KatanovDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Alexandra KernDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Fayola LevineDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Pam LeybengrubDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.
Olorunseun OgunwobiDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.ORCID 0000-0003-3388-2137
Gu XiaoDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.ORCID 0000-0001-8433-9121
Zhaohui FengDepartment of Radiation Oncology, Rutgers Cancer Institute, Rutgers, State University of New Jersey, New Brunswick, NJ 08901, USA.ORCID 0000-0002-8912-6456
Jill BargonettiDepartment of Biological Sciences, Hunter College, City University of New York, Belfer Building, New York, NY 10021, USA.ORCID 0000-0003-2692-0991

Funding

RISE Program Hunter College Option IIIR25GM060665 · NIGMS · HUNTER COLLEGE · PI ORTIZ, BENJAMIN D.,, SERRANO, PETER A · 2000 to 2022
$22.8M
TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221704 · NCI · HUNTER COLLEGE · PI Ming-Chin Yeh · 2018 to 2026
$10.6M
NCI NIH HHS U54 CA221704NIGMS NIH HHS R25 GM060665NIH HHS 1U54TW221704-05A1
6 · The paper itself

Abstract

backgroundThe metastasis-promoting G-protein-coupled receptor CXC Receptor 4 (CXCR4) is activated by the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1). The CXCL12/CXCR4 pathway in cancer promotes metastasis but the molecular details of how this pathway cross-talks with oncogenes are understudied. An oncogene pathway known to promote breast cancer metastasis in MDA-MB-231 xenografts is that of Mouse Double Minute 2 and 4 (MDM2 and MDM4, also known as MDMX). MDM2 and MDMX promote circulating tumor cell (CTC) formation and metastasis, and positively correlate with a high expression of CXCR4. Interestingly, this MDMX-associated upregulation of CXCR4 is only observed in cells grown in the tumor microenvironment (TME), but not in MDA-MB-231 cells grown in a tissue culture dish. This suggested a cross-talk signaling factor from the TME which was predicted to be CXCL12 and, as such, we asked if the exogenous addition of the cell non-autonomous CXCL12 ligand would recapitulate the MDMX-dependent upregulation of CXCR4.

methodsWe used MDA-MB-231 cells and isolated CTCs, with and without MDMX knockdown, plus the exogenous addition of CXCL12 to determine if MDMX-dependent upregulation of CXCR4 could be recapitulated outside of the TME context. We added exogenous CXCL12 to the culture medium used for growth of MDA-MB-231 cells and isogenic cell lines engineered for MDM2 or MDMX depletion. We carried out immunoblotting, and quantitative RT-PCR to compare the expression of CXCR4, MDM2, MDMX, and AKT activation. We carried out Boyden chamber and wound healing assays to assess the influence of MDMX and CXCL12 on the cells' migration capacity.

resultsThe addition of the CXCL12 chemokine to the medium increased the CXCR4 cellular protein level and activated the PI3K/AKT signaling pathway. Surprisingly, we observed that the addition of CXCL12 mediated the upregulation of MDM2 and MDMX at the protein, but not at the mRNA, level. A reduction in MDMX, but not MDM2, diminished both the CXCL12-mediated CXCR4 and MDM2 upregulation. Moreover, a reduction in both MDM2 and MDMX hindered the ability of the added CXCL12 to promote Boyden chamber-assessed cell migration. The upregulation of MDMX by CXCL12 was mediated, at least in part, by a step upstream of the proteasome pathway because CXCL12 did not increase protein stability after cycloheximide treatment, or when the proteasome pathway was blocked.

conclusionsThese data demonstrate a positive feed-forward activation loop between the CXCL12/CXCR4 pathway and the MDM2/MDMX pathway. As such, MDMX expression in tumor cells may be upregulated in the primary tumor microenvironment by CXCL12 expression. Furthermore, CXCL12/CXCR4 metastatic signaling may be upregulated by the MDM2/MDMX axis. Our findings highlight a novel positive regulatory loop between CXCL12/CXCR4 signaling and MDMX to promote metastasis.

Indexed as

chemokine signalingcirculating tumor cells (CTCs)CXCR4MDM2MDMXmetastasisPI3K/AKT signalingtriple-negative breast cancer (TNBC)tumor microenvironment (TME)

Identifiers

PMID39766093
PMCPMC11674518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.